New Hopes and Fears for Alzheimer's Patients
Newsweek US|December 30, 2022
A new drug offers modest slowing of the disease in its early stages. But are the benefits worth the risks?
By Meghan Gunn
New Hopes and Fears for Alzheimer's Patients

After many decades of little or no progress in treating the dementia associated with Alzheimer's, a new drug now offers hope to patients and caregivers. Lecanemab, announced late last month, was found in clinical trials to slow cognitive decline in early-stage Alzheimer's patients. "It's an extremely encouraging result," says Dr. David Wolk, co-director of the University of Pennsylvania's Penn Memory Center.

The arrival of lecanemab comes with some big caveats, however. The drug has significant health risks, including bleeding and brain swelling. It's expensive drug manufacturer Esai estimates the annual price of treatment would be somewhere between $9,249 and $35,605, and it's unclear what insurance will cover. And the drug has only a modest effect on the debilitating progress of Alzheimer's.

Some scientists are also having second thoughts about the strategy that led to lecanemab-namely, trying to slow Alzheimer's solely by inhibiting the buildup of beta-amyloid, a protein that accumulates in the brain cells to form plaques. After three decades of chasing one failed treatment after another and burning through billions of dollars in research funding, lecanemab is the first unequivocally successful plaque-inhibiting treatment for Alzheimer's. (A similar drug, Aduhelm, was approved last year by the U.S. Food and Drug Administration to some controversy.) Many scientists now think amyloid plaque is only one of many factors in causing the disease's debilitating effects and call for new approaches.

The FDA is expected to decide on an accelerated approval status for lecanemab on January 6, which would enroll additional patients in new trials. If those are successful, full approval would likely arrive late next year.

This story is from the December 30, 2022 edition of Newsweek US.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the December 30, 2022 edition of Newsweek US.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM NEWSWEEK USView All
Ramy Youssef
Newsweek US

Ramy Youssef

DESCRIBING RAMY YOUSSEF'S WORK ISN'T EASY, BECAUSE HE REFUSES TO settle on just one thing. \"I feel really inspired to connect in the way that it makes sense.\"

time-read
2 mins  |
March 29 - April 05, 2024 (Double Issue)
Tobias Menzies
Newsweek US

Tobias Menzies

HOW MUCH DO WE REALLY KNOW ABOUT THE assassination of President Abraham Lincoln? That's a question Tobias Menzies hopes to answer in Apple TV+'s Manhunt (March 15).

time-read
1 min  |
March 29 - April 05, 2024 (Double Issue)
The Fall and Rise of Katt Williams
Newsweek US

The Fall and Rise of Katt Williams

He's had a string of run-ins with the law, yet the comedian's popularity continues to grow-with a recent podcast appearance blowing up the internet

time-read
6 mins  |
March 29 - April 05, 2024 (Double Issue)
AMERICA'S Greatest Workplaces for JOB STARTERS 2024
Newsweek US

AMERICA'S Greatest Workplaces for JOB STARTERS 2024

Getting a career started is never easy. First-day stumbling blocks can give way to larger questions about choosing the right career path. Imposter syndrome, information overload, the challenge of new colleagues: it's almost enough to make you miss the routine of sending out endless résumés to online job descriptions.

time-read
3 mins  |
March 29 - April 05, 2024 (Double Issue)
THE INCONCEIVABLE SEARCH FOR SPERM
Newsweek US

THE INCONCEIVABLE SEARCH FOR SPERM

Making MOTHERHOOD a reality in the face of virtually every cultural taboo

time-read
10+ mins  |
March 29 - April 05, 2024 (Double Issue)
I'm Suing Harvard Over Rife Antisemitism
Newsweek US

I'm Suing Harvard Over Rife Antisemitism

I applied to the university's Divinity School to be an ambassador for Orthodox Jews and build bridges with other cultures; instead I'm battling discrimination

time-read
4 mins  |
March 29 - April 05, 2024 (Double Issue)
Gen Z's Pockets Full of Cash
Newsweek US

Gen Z's Pockets Full of Cash

Digital wallets and bank cards might appear to be the modern way to pay, but physical money is making a comeback among young adults

time-read
4 mins  |
March 29 - April 05, 2024 (Double Issue)
Biden's Age Problem Tears Democrats Apart
Newsweek US

Biden's Age Problem Tears Democrats Apart

After being depicted as an 'elderly man with a poor memory,' questions surrounding the president's advanced years are dividing his party

time-read
6 mins  |
March 29 - April 05, 2024 (Double Issue)
Country Has Won Our Achy Breaky Hearts
Newsweek US

Country Has Won Our Achy Breaky Hearts

The genre has never been so popular-and with the likes of Beyoncé reminding fans of its roots, its mainstream appeal looks set to grow and grow

time-read
6 mins  |
March 22, 2024
'Deadly Risk' of Fat-Loss Drugs
Newsweek US

'Deadly Risk' of Fat-Loss Drugs

Diabetes treatment Ozempic has become popular among dieters due to its weightloss side effect, but a study warns of a link between the drug and suicidal thoughts

time-read
5 mins  |
March 22, 2024